Ariceum Therapeutics, a biotech company specializing in radiopharmaceutical products for hard-to-treat cancers, has announced the dosing of the first patient with satoreotide in its Phase Ib study targeting extensive stage small cell lung cancer (ES-SCLC). The study is being conducted at the GenesisCare Murdoch Theranostics and Molecular Imaging Centre in Perth, Australia.
The Phase Ib study is a multicentre, open label investigation focusing on the safety and tolerability of a 'theranostic pair' consisting of 68Ga-Satoreotide Trizoxetan (SSO120) for diagnostic imaging and 177Lu-satoreotide tetraxetan (SSO110) for therapeutic purposes. The primary objective is to determine a recommended Phase 2 dose and schedule.
Satoreotide is a first-in-class antagonist of the somatostatin receptor 2 (SST2), which is overexpressed in certain cancers, including small cell lung cancer. The study, named LuSato-1, involves patients receiving a diagnostic imaging agent to identify SST2 expression in tumors, followed by escalating doses of satoreotide alongside the immunotherapy atezolizumab during the maintenance phase of treatment.
Manfred Rüdiger, PhD, CEO of Ariceum Therapeutics, highlighted the significance of this milestone, emphasizing the potential of satoreotide to deliver positive outcomes for ES-SCLC patients through a highly targeted 'search and destroy' approach. Germo Gericke, Chief Medical Officer, noted the promise of combining targeted radiotherapy with immune checkpoint blockade to enhance the therapeutic effect of maintenance therapy.
An abstract detailing the LuSato-1 study will be presented at the European Association of Nuclear Medicine Congress 2023 in Vienna, Austria, on September 10, 2023. Ariceum Therapeutics, founded in 2021 and headquartered in Berlin, is dedicated to developing innovative treatments for neuroendocrine and other aggressive cancers, leveraging the legacy of Marie Curie's contributions to cancer therapy.
